{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Feasibility of product generation was examined by assessing the number of AUTO2 successfully manufactured as a fraction of the number of patients undergoing leukapheresis (all patients registered).","groups":[{"description":"Relapsed or refractory myeloma patients","id":"OG000","title":"AUTO2"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Proportion of Patients for Whom an AUTO2 Product Can be Generated","type":"SECONDARY","unitOfMeasure":"Participants"}